INNEOVA Holdings Limited Reports Q3 2026 Financial Results and Strategic Expansion

11/19/2026
Impact: 65
Consumer Cyclical

INNEOVA Holdings reported record nine-month revenue of $53.59 million, up 17.6% year over year. In Q3, gross margin rose to 12.6%, up 465 basis points sequentially, and adjusted EBITDA improved about 18%; since year-end, total debt fell 34% and liabilities declined 18.2%, including settlement of an $8.0 million convertible note. The company entered Saudi Arabia through a five-year distribution agreement targeting an initial 126,000-unit order, expanded its Pharma Cell partnership in Albania, and signed a DIABIT-IS X commercialization agreement in Greece. By September 30, it had repurchased 255,600 shares under its $5.0 million buyback program.

AI summary, not financial advice

Share: